United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - sulfasalazine - gastro-resistant tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - sulfasalazine - gastro-resistant tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - sulfasalazine - oral suspension - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - sulfasalazine - oral suspension - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - sulfasalazine - oral tablet - 500mg

Israel - English - Ministry of Health

medison pharma ltd - galsulfase - concentrate for solution for infusion - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - elosulfase alfa, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: arginine hydrochloride; monobasic sodium phosphate monohydrate; sodium acetate trihydrate; water for injections; polysorbate 20; sorbitol - vimizim is indicated for the treatment of mucopolysaccharidosis type iva (mps iva; morquio a syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - idursulfase, quantity: 6 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate; polysorbate 20 - for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii) for the long term treatment of patients with hunter syndrome (mucoplysaccharidosis ii, mps ii).

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - galsulfase, quantity: 5 mg - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate heptahydrate; polysorbate 80; sodium chloride - for the long-term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi - n acetylgalactosamine 4-sulfatase deficiency)

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

chemo centroamericana,s.a - sulfasalazina - sulfasalazina....500.00 mg